Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study

Published:2024-01 Issue: Volume:119 Page:76-84
ISSN:0967-5868
Container-title:Journal of Clinical Neuroscience
language:en
Short-container-title:Journal of Clinical Neuroscience

Author:

GomezMancilla Baltazar,Meriggioli Matthew N.,Genge Angela,Roubenoff Ronenn,Espié Pascal,Dupuy Cyrielle,Hartmann Nicole,Pezous Nicole,Kinhikar Arvind,Tichy Mia,Dionne Annie,Vissing John,Andersen Henning,Schoser Benedikt,Meisel Andreas,Jordan Berit,Devlikamova Farida,Poverennova Irina,Stuchevskaya Fatima,Lin Thy-Sheng,Rush James S.,Gergely Peter

Funder

Novartis Institutes for BioMedical Research

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Physiology (medical),Neurology (clinical),Neurology,General Medicine,Surgery

Reference33 articles.

1. Epidemiology of myasthenia gravis in Ontario, Canada;Breiner;Neuromuscul Disord,2016

2. International consensus guidance for management of myasthenia gravis: executive summary;Sanders;Neurology,2016

3. Myasthenia gravis: a review;Jayam Trouth;Autoimmune Dis,2012

4. Treatment of MuSK-associated myasthenia gravis;El-Salem;Curr Treat Options Neurol,2014

5. Seronegative myasthenia gravis: disease severity and prognosis;Romi;Eur J Neurol,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP